PharmaCyte Biotech, Inc. - Common Stock (NQ:PMCB)

0.3901 -0.0100 (-2.50%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about PharmaCyte Biotech, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Wondering what's happening in today's after-hours session? ↗

January 15, 2026

Via Chartmill

On Friday, there are stocks with unusual volume. Let's take a look. ↗

December 05, 2025

The trading volume of these stocks is deviating from the norm in today's session.

Via Chartmill

Keep an eye on the top gainers and losers in Thursday's session. ↗

December 04, 2025

Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

Which stocks are most active on Thursday? ↗

December 04, 2025

Let's dive into the action on the US markets on Thursday. Here are the most active stocks that are driving the market today.

Via Chartmill

PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q3 2024 ↗

March 19, 2024

PharmaCyte Biotech just reported results for the third quarter of 2024.

Via InvestorPlace

Let's take a look at the stocks that are in motion in today's session. ↗

December 04, 2025

Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Gapping stocks in Thursday's session ↗

December 04, 2025

The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.

Via Chartmill

Get insights into the top gainers and losers of Tuesday's after-hours session. ↗

November 25, 2025

After the closing bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

Via Chartmill

PMCB Stock Jumps 25% After Company Sells Stake In Femasys ↗

November 25, 2025

PharmaCyte noted that it now has approximately $25 million in marketable securities, in addition to roughly $20 million in cash.

Via Stocktwits

PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

November 25, 2025

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications

September 02, 2025

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing

August 20, 2025

From PharmaCyte Biotech, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

August 19, 2025

Via Benzinga

PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors

August 18, 2025

From PharmaCyte Biotech, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

May 27, 2025

Via Benzinga

PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease

May 21, 2024

From PharmaCyte Biotech, Inc.

Via Business Wire

PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024 ↗

December 18, 2023

PharmaCyte Biotech just reported results for the second quarter of 2024.

Via InvestorPlace

PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.

November 15, 2023

From PharmaCyte Biotech, Inc.

Via Business Wire

Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech

November 15, 2023

From Femasys Inc.

Via GlobeNewswire

PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology

October 31, 2023

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech Announces Final Results of Tender Offer

June 15, 2023

From PharmaCyte Biotech, Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 11, 2023

Via Benzinga

PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share

May 11, 2023

From PharmaCyte Biotech, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Tuesday ↗

September 26, 2023

On Tuesday, 386 stocks made new 52-week lows.

Via Benzinga

PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan

February 02, 2023

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital

August 15, 2022

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation

July 28, 2022

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study

July 21, 2022

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study

July 19, 2022

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022

July 11, 2022

From PharmaCyte Biotech, Inc.

Via Business Wire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.